#USA #Creatv Bio #Monmouth Junction #CytoDyn #LifeTracDx

Collaboration to Improve Cancer Treatment

Creatv Bio, a division of Creatv MicroTech, has recently initiated an innovative partnership with CytoDyn, based in Vancouver, Washington. This collaboration centers around the LifeTracDx® liquid biopsy test, which is set to play a crucial role in a Phase 2 study focusing on patients with relapsed or refractory metastatic colorectal cancer (mCRC).

Phase 2 Study Overview

CytoDyn's Phase 2 clinical trial, designated as NCT06699836, targets 60 participants who have a history of treatment for mCRC. The study explores the effects of leronlimab, an experimental treatment, when combined with TAS-102 and Bevacizumab. This trial will leverage the LifeTracDx® blood test at multiple time points throughout the treatment process. By examining various patient data, researchers aim to gather valuable insights about the therapy's impact on PD-L1 expression levels, an essential protein that plays a significant role in immune response regulation.

Understanding LifeTracDx®

The LifeTracDx® blood test utilizes advanced methodologies to analyze circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells, which are associated with tumor progression. By monitoring these cell types, healthcare providers can obtain real-time information regarding tumor responses to treatment, ultimately contributing to verifying therapy effectiveness.

Potential of Leronlimab

Past research has indicated that leronlimab can induce PD-L1 expression in CTCs and CAMLs, demonstrating promising effects among patients with metastatic breast cancer. In 88% of treated patients, increases in PD-L1 levels were observed, supporting the hypothesis that leronlimab may have the capacity to transform 'cold' tumors into 'hot' tumors. This transformation is critical because 'hot' tumors tend to respond better to immunotherapy, offering new hope to clinical interventions in oncology.

Monitoring with LifeTracDx®

By utilizing LifeTracDx®, Creatv Bio aims to evaluate PD-L1 expression in colorectal cancer patients at various treatment stages. Initial results indicate that tracking these expressions could help identify patients experiencing increased PD-L1 levels, thereby enhancing treatment responses and personalization of subsequent therapies.

Creatv Bio's Mission

Creatv Bio's overarching goal within the cancer diagnostics sphere is to develop impactful screening tools and tests that aid both patients and pharmaceutical companies in drug development. Their CLIA accredited laboratory in New Jersey facilitates diverse testing applications, including prospective assessments of therapy responses, cancer aggressiveness evaluation, and early detection of recurrent cancers.

About CytoDyn

CytoDyn is dedicated to developing leronlimab, a pioneering humanized monoclonal antibody that targets the CCR5 receptor. This receptor plays a critical role in regulating immune function, making it integral to treating cancer as well as infectious and autoimmune diseases. CytoDyn emphasizes innovation and patient-centric solutions, striving to enhance the quality of life through advanced therapeutic options.

The collaboration between Creatv Bio and CytoDyn signifies a promising step forward in the fight against metastatic colorectal cancer, with the LifeTracDx® blood test potentially paving the way for new insights into cancer treatment efficacy. For ongoing updates and additional information about these pioneering efforts, check out Creatv Bio’s website.